Insights
Newsletters
European Antitrust Bimonthly Bulletin – September/October 2026
The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
Newsletters
2026 Mid-Year Technology and Life Sciences PIPE and RDO Report
Wilson Sonsini is pleased to present the 2026 Mid-Year Technology and Life Sciences PIPE and RDO Report, analyzing 103 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences companies between January 1 and June 30, 2026.
Newsletters
2026 Mid-Year Technology and Life Sciences IPO Report
Wilson Sonsini's 2026 Mid-Year Technology and Life Sciences IPO Report presents in-depth analysis related to 37 initial public offerings (IPOs) with deal values exceeding $75 million or direct listings completed by U.S.-based technology and life sciences companies between January 1 and June 30, 2026.
All Results
Alerts
11.13.26
Major EU Consumer Law Reform for Online Businesses: European Commission Proposes Digital Fairness Act
On November 11, 2026, the European Commission (EC) published its proposal for a Digital Fairness Act (DFA), which would significantly reform the European Union (EU) consumer protection framework and introduce new restrictions on addictive design, influencer marketing, manipulative practices, unfair personalization, and in-game spending. As proposed, the DFA would provide the EC with direct powers to investigate and impose fines of up to six percent of worldwide annual revenue.
Client Highlights
11.13.26
Wilson Sonsini Advises Crosspoint Capital on Kindo's $30 Million Financing
On November 12, 2026, Kindo, an AI agent management platform, announced a $30 million raise co-led by Crosspoint Capital and Forgepoint Capital, bringing total funding to $57.6 million. TFX Capital and CircleRock Capital joined, alongside existing investors. Wilson Sonsini Goodrich & Rosati advised Crosspoint Capital on the transaction.
Client Highlights
11.13.26
Wilson Sonsini Advises Delix Therapeutics on IP Matters Related to $100 Million Series C Financing
On November 9, 2026, Delix Therapeutics (Delix), a clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens, announced the closing of an oversubscribed $100 million Series C financing. The round was led by Johnson & Johnson Innovation – JJDC, Inc., the corporate venture capital organization of Johnson & Johnson, and SV Health Investors’ Dementia Discovery Fund, with participation from existing investors including RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, and Bail Capital, as well as new investors, including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures, among others. Wilson Sonsini Goodrich & Rosati advised Delix on the intellectual property matters related to the transaction.
News Articles
11.12.26
Wilson Sonsini Partners Sachin Kohli and Demian Ahn Contribute to Diligent’s Q4 GC Risk Index Report
Mergers & Acquisitions partner Sachin Kohli and Data, Privacy, and Cybersecurity partner Demian Ahn recently contributed to the Q4 edition of the General Counsel (GC) Risk Index report published by Diligent Institute. This report explores how legal leaders assess the current risk environment, what risks are driving those assessments, how AI governance is structured, how boards are preparing to oversee AI, and whether organizations are ready to respond to cyber events and related disclosure obligations.
Alerts
11.11.26
Delaware Corporation Law Council Proposes Amendments on Stockholder Proposals
On November 9, 2026, the Delaware Corporation Law Council (the Council)—a body of practitioners in Delaware that vets and proposes amendments to the Delaware General Corporation Law—announced potential statutory amendments addressing stockholders’ ability to make non-binding proposals at public company annual meetings. The proposed amendments follow the recent proposal by the U.S. Securities and Exchange Commission (SEC), described here,1 to rescind Rule 14a-8 of the Securities Exchange Act of 1934, which has largely regulated non-binding stockholder proposals for the last 80 years. The SEC’s proposal is pending and as was announced in August 2026, the SEC staff has discontinued its practice of responding to requests from companies for no-action relief to exclude a proposal under Rule 14a-8. The proposed Delaware amendments (the Amendments) are written to become effective if and when the SEC rescinds Rule 14a-8 and would provide the new replacement regime for Delaware corporations. The Amendments would clarify the landscape for Delaware corporations because existing Delaware law does not expressly address the subject.
Client Highlights
11.11.26
Wilson Sonsini Advises PacBio on $100 Million At-the-Market Stock Offering
On November 10, 2026, Pacific Biosciences of California, Inc. (PacBio), developer of the world’s most advanced sequencing technologies, entered into a sales agreement with Allen & Company LLC to offer up to $100 million of its common stock through an at-the-market program. Under the terms of the agreement, PacBio may offer and sell shares of its common stock having an aggregate offering price of up to $100 million from time to time through or to Allen & Company LLC, acting as PacBio’s sales agent or principal. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.
PacBio intends to use the proceeds from this offering, together with existing cash, cash equivalents, and investments, for research and development and working capital and general corporate purposes.
The Wilson Sonsini team that advised PacBio on the transaction included Andrew Hoffman, Zachary Myers, Annie Giomi, James Keegan, and Mounika Yepuri.
For more information, please see PacBio’s prospectus supplement.
PacBio intends to use the proceeds from this offering, together with existing cash, cash equivalents, and investments, for research and development and working capital and general corporate purposes.
The Wilson Sonsini team that advised PacBio on the transaction included Andrew Hoffman, Zachary Myers, Annie Giomi, James Keegan, and Mounika Yepuri.
For more information, please see PacBio’s prospectus supplement.
Newsletters
11.10.26
European Antitrust Bimonthly Bulletin – September/October 2026
The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
Client Highlights
11.10.26
Firm Represents Veteran Ventures Capital as Lead Investor in $6.95 Million Aformic Financing
On November 4, 2026, Veteran Ventures Capital (VVC) announced that it led a $6.95 million investment in Aformic, a robotics company that designs and deploys autonomous mobile robots and fleet-management software. Wilson Sonsini Goodrich & Rosati advised VVC on the transaction.
Client Highlights
11.10.26
Wilson Sonsini Advises Ancep on $8.5 Million Funding Round
On November 10, 2026, Ancep, a London-based start-up building artificial intelligence (AI) agents for commercial insurance brokers, emerged from stealth and announced it raised $8.5 million in a funding round led by Creandum. The round also included participation from Kleiner Perkins and Vicus Ventures, alongside angel investors including Christa Davies, former chief financial officer of Aon, and operators from OpenAI, Anthropic, and Google DeepMind. Ancep will use the new funds to support growth and hiring. Wilson Sonsini Goodrich & Rosati advised Ancep on the transaction.
Client Highlights
11.10.26
Wilson Sonsini Advises Graphon Labs on $35 Million Series A
On November 10, 2026, Graphon Labs, an applied artificial intelligence (AI) lab building Persistent Intelligence to power the next generation of AI agents and accelerate progress toward artificial general intelligence, announced a $35 million Series A led by RRE Ventures, with participation from HP, Energy Impact Partners, Hitachi Ventures, and Gaia VC. Wilson Sonsini Goodrich & Rosati advised Graphon Labs on the transaction.
Bylined Articles
11.09.26
Law360 Article: “What FTC Publicis Deal Means for Data Infrastructure M&A”
Wilson Sonsini partners Michelle Yost Hale and Matthew McDonald recently authored a Law360 article examining what the Federal Trade Commission’s (FTC) proposed consent order in Publicis Groupe SA’s $2.2 billion acquisition of LiveRamp means for data infrastructure mergers and acquisitions. The piece explains that the October 19 order resolves a purely vertical theory of harm centered on Publicis’ potential control over LiveRamp’s previously neutral data connectivity services, and requires Publicis, for five years, to provide nondiscriminatory access, maintain firewalls for customer data, and submit to compliance audits.
Client Highlights
11.09.26
Wilson Sonsini Advises HZO on Acquisition by Forge Nano
On November 5, 2026, Forge Nano Holdings, Inc. (Forge Nano), a semiconductor equipment and advanced materials company whose Atomic Layer Deposition (ALD) technology serves AI-era chip manufacturing and defense battery applications, announced that it has completed the acquisition of HZO, Inc., a leading provider of protective nanocoatings for electronics. The combination pairs Forge Nano’s ALD platform with HZO’s high-volume Parylene and thin-film protective coating business and its blue-chip customer base in the consumer electronics, energy, IoT, medical, and automotive industries. Wilson Sonsini Goodrich & Rosati advised HZO on the transaction.